What is Semax?

By ClearCost Wellness, a Dataweave Inc publication · Published 24 October 2026 · Updated 24 October 2026

In short: Semax is a synthetic heptapeptide developed in Russia, sold mostly in nasal format for research use only. It is studied in cognitive and neurological research; the human literature is small and mostly Russian, never FDA-reviewed. Semax is not FDA-approved. It was considered for the 503A Bulks List at the FDA advisory committee's July 2026 meeting; committee recommendations are non-binding advice to the FDA.

Semax is a synthetic peptide developed in Russia and studied in cognitive and neurological research. Unlike most compounds in this market, it is sold primarily in a nasal format rather than as an injectable vial - one reason it draws interest from buyers who would never consider an injection-format product.

The basics

• Type: a synthetic heptapeptide - a modified fragment related to the ACTH(4-7) sequence with an added stabilizing tripeptide.
• Origin: developed by Russian researchers; a Semax preparation has been registered in Russia in nasal-drop form. That registration has no standing with the FDA.
• Research focus: laboratory and small clinical studies examine Semax in relation to cognitive and neuroprotective questions.
• Formats sold: nasal spray bottles (listed around $42) and lyophilized vials, commonly 10 mg.

What the evidence actually shows

The human literature on Semax consists of small studies, predominantly Russian, that have never been through FDA review. That is a thinner base than marketing in this niche usually implies. Claims circulating in vendor copy about the nasal format's absorption come from guides and sellers, not from FDA-reviewed data, and should be read as claims.

Semax is frequently sold alongside Selank, a related research peptide studied in anxiety research, also in small Russian trials. Selank is the more commoditised of the two: price tracking (PeptidePrices, checked 24 October 2026) found a lowest tracked 10 mg listing of $17.97 across 200 tracked vendors - a useful benchmark for what "normal" pricing looks like in this market.

Regulatory status (October 2026)

At the FDA's Pharmacy Compounding Advisory Committee meeting on 23-24 July 2026, Semax was considered for inclusion on the 503A Bulks List. Two things apply, as for every compound considered:

• Committee recommendations are non-binding advice to the FDA; inclusion would require FDA rulemaking.
• The meeting was a nomination review, not a drug-approval process; Semax is not FDA-approved.
• Selank was not among the compounds considered in July 2026.

What Semax costs

Price tracking by PeptidePrices (checked 24 October 2026) shows the lowest 10 mg listing at $17.97 across 205 tracked vendors, while trade-level prices sit well below retail. Nasal-format bottles are also listed in this market. The spread between the cheapest and most expensive listings for identical items is the story of this whole market; the tracked ranges for every compound we cover are on the price-comparison page.

What to check before buying any research peptide

• Batch-specific COA from third-party testing, tied to the lot you receive.
• Identity + purity methods stated on the COA (HPLC and mass spectrometry).
• Format honesty: a nasal product and a lyophilized vial are different formats with different research contexts; vendor copy that blurs them is a red flag.

Related reading

• What is MOTS-c? - the longevity-research counterpart from the same July 2026 vote.
• Research peptide price comparison - including Selank's 200-vendor benchmark.
• FAQ: what the July 2026 FDA votes actually changed